HealthcareServices

Treatment-Resistant Depression Global Forecast: Market to Scale Up to $2.59 Billion by 2030 at 6.7% CAGR

March 3, 2026March 3, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the treatment-resistant depression market from 2026–2035 with trusted insights from The Business Research Company

By how much is the Treatment-Resistant Depression Market expected to grow between 2026 and 2030?

The treatment-resistant depression market has experienced significant growth in recent years. It is anticipated to expand from $1.87 billion in 2025 to $2 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.9%. This historical growth can be attributed to factors such as the rising prevalence of major depressive disorder, the limited efficacy of conventional antidepressants, an increased diagnosis of refractory depression cases, the expansion of psychiatric specialty clinics, and the growing acceptance of advanced mental health therapies.

The treatment-resistant depression market size is anticipated to experience significant growth in the coming years. It is projected to expand to $2.59 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.7%. This expansion during the forecast period can be attributed to increasing investments in precision psychiatry, the growing approval of ketamine and esketamine therapies, the expansion of biomarker-driven treatment selection, a rising demand for long-term depression management solutions, and the increased use of digital therapeutic support tools. Key trends identified for the forecast period include the increasing adoption of novel rapid-acting antidepressants, the rising use of neuromodulation therapies, a growing focus on personalized psychiatry approaches, the expansion of psychedelic-based treatment research, and an enhanced integration of digital mental health tools.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23546&type=smp

Which Drivers Are Influencing Market Acceleration In The Treatment-Resistant Depression Market?

The widespread occurrence of mental disorders is anticipated to drive the growth of the treatment-resistant depression market moving forward. Mental disorders represent a broad category of conditions that impact an individual’s cognitive, emotional, and behavioral functioning, often leading to significant distress and impairment in daily life. This high prevalence is fueled by factors such as genetic predisposition, as inherited genetic variations can influence brain chemistry and heighten susceptibility to conditions like depression, anxiety, and schizophrenia. Treatment-resistant depression (TRD) offers support to mental disorder patients by encouraging the use of more personalized and advanced treatments when standard therapies are ineffective, thereby helping to improve their chances of recovery and quality of life. For instance, in November 2023, according to the American Psychological Association (APA), a US-based scientific and professional organization, among adults, those aged 18 to 34 reported the highest rate of mental illnesses at 50% in 2023, while adults aged 35 to 44 experienced the largest increase in diagnoses, with 45% reporting a mental illness. Therefore, the significant prevalence of mental disorders is propelling the growth of the treatment-resistant depression market.

What Segments Are Identified Within The Structure Of The Treatment-Resistant Depression Market?

The treatment-resistant depression market covered in this report is segmented –

1) By Drug Class: Selective Serotonin Reuptake Inhibitors (SSRIs), Monoamine Oxidase Inhibitors, Tricyclic Antidepressants, Psychedelics

2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Selective Serotonin Reuptake Inhibitors (SSRIs): Fluoxetine, Sertraline, Paroxetine, Citalopram, Escitalopram

2) By Monoamine Oxidase Inhibitors (MAOIs): Phenelzine, Tranylcypromine, Isocarboxazid, Selegiline

3) By Tricyclic Antidepressants (TCAs): Amitriptyline, Nortriptyline, Imipramine, Clomipramine, Doxepin

4) By Psychedelics: Ketamine, Esketamine, Psilocybin, Lysergic Acid Diethylamide (LSD), 3,4-Methylenedioxymethamphetamine (MDMA)

How Are New Market Trends Shaping The Landscape Of The Treatment-Resistant Depression Market?

Major companies operating in the treatment-resistant depression market are concentrating on developing innovative therapies like monotherapy to address unfulfilled patient needs, boost efficacy, and lessen side effects. Monotherapy refers to the application of a single treatment or medication to manage a condition, rather than using a combination. It helps in treating treatment-resistant depression by presenting a singular, focused treatment that might be more effective for patients who have not responded to multiple medications. For instance, in January 2025, Johnson & Johnson Services Inc., a US-based pharmaceutical, biotechnology, and medical technology company, announced the U.S. Food and Drug Administration (FDA), a US-based government regulatory body, had approved SPRAVATO (esketamine) nasal spray, a fast-acting treatment for adults with treatment-resistant depression (TRD). SPRAVATO is administered alongside an oral antidepressant when patients have not adequately responded to at least two other antidepressant therapies. The drug’s rapid effects tackle the limitations of traditional antidepressants, which often take weeks to demonstrate results. As a derivative of ketamine, esketamine functions by targeting the brain’s NMDA receptors, potentially improving mood within hours. This approval marked a significant advancement in the field of mental health treatment.

Which Key Players Are Driving Competition In The Treatment-Resistant Depression Market?

Major companies operating in the treatment-resistant depression market are Pfizer Inc., Johnson & Johnson Services Inc., Neurocrine Biosciences Inc., Relmada Therapeutics Inc., Neuronetics Inc., COMPASS Pathways, BrainsWay Ltd., Magstim Company Limited, MindMed, Alto Neuroscience, Sage Therapeutics Inc., MindBio Therapeutics Ltd., Reunion Neuroscience

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/treatment-resistant-depression-global-market-report

How Does The Treatment-Resistant Depression Market Perform Across Major Global Regions?

North America was the largest region in the treatment-resistant depression market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the treatment-resistant depression market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Treatment-Resistant Depression Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23546&type=smp

Browse Through More Reports Similar to the Global Treatment-Resistant Depression Market 2026, By The Business Research Company

Behavioral Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/behavioral-therapy-global-market-report

Major Depressive Disorder Market Report 2026

https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

Music Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/music-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795